You are here

Study to Evaluate PF-04965842 in Patients With Moderate to Severe Psoriasis

Last updated on March 11, 2019

FOR MORE INFORMATION
Study Location
Total Skin and Beauty Dermatology Center, PC
Birmingham, Alabama, 32505 United States
Contact
1-800-718-1021
Eligibility criteria
Condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Plaque Psoriasis
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
18-65 years
Inclusion criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

1. Have a diagnosis of plaque psoriasis for at least 6 months prior to first study dose.

2. Have plaque type psoriasis covering at least 15% of total BSA at Day 1 (at the time of
the first study dose).

3. Have a PASI score of 12 or greater at Day 1 (at the time of the first study dose).

4. Be a candidate for phototherapy or systemic treatment of psoriasis (either naïve or
history of previous treatment).

Exclusion criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details

1. Currently have non plaque forms of psoriasis, eg, erythrodermic, guttate, or pustular
psoriasis.

2. 3. Have current drug induced psoriasis, eg, a new onset of psoriasis or an
exacerbation of psoriasis from beta blockers, calcium channel blockers, antimalarial
drugs or lithium.

3. Have received any of the following treatment regimens specified in the timeframes
outlined below:

Within 9 months of first dose of study drug:

? Ustekinumab (Stelara).

Within 12 weeks of first dose of study drug:

? Any experimental therapy for psoriasis or rheumatoid arthritis.

Within 4 8 weeks of first dose of study drug:

- Biologic therapies for psoriasis have discontinuation periods determined from
approximately 5x half life of the respective biologic:

- 4 weeks: etanercept (Enbrel).

- 8 weeks: infliximab (Remicade), adalimumab (Humira).

Within 4 weeks of first dose of study drug:

- Systemic treatments other than biologics that could affect psoriasis (eg, oral or
injectable corticosteroids, retinoids, methotrexate, cyclosporine, fumaric acid
derivatives, sulfasalazine, hydroxycarbamide (hydroxyurea), azathioprine).

- Phototherapy and psoralen plus ultraviolet A therapy (PUVA).

- Other - intramuscular gold, immunization with any live virus vaccination (eg,
FluMist), herbal medications.

Within 2 weeks of first dose of study drug:

- Topical treatments that could affect psoriasis (eg, corticosteroids, tars,
keratolytics, anthralin, vitamin D analogs, and retinoids).

- Phototherapy with ultraviolet B (UVB) (narrowband or broadband).

NCT02201524
Pfizer
Terminated
Study to Evaluate PF-04965842 in Patients With Moderate to Severe Psoriasis

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

call now

Try a new search

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting the study website. Please see the references below:

BY PHONE

Pfizer Clinical Trials Contact Center

1-800-718-1021

BY EMAIL

Contact

[email protected]

Call Now